Freeline, Wugen & Jnana Secure EMA PRIME Designations For Novel Treatments
Executive Summary
A one-time gene therapy candidate for Gaucher disease, an allogeneic CAR-T cell therapy for difficult-to-treat blood cancers, and a potentially first-in-class drug for treating hyperphenylalaninemia have made it onto the European Medicines Agency’s priority medicines scheme.